The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC).
 
Adrienne Gropper Waks
No Relationships to Disclose
 
Ofir Cohen
No Relationships to Disclose
 
Bose Kochupurakkal
Employment - Amgen (I)
Stock and Other Ownership Interests - Amgen (I)
Research Funding - Lilly
 
Dewey Kim
Patents, Royalties, Other Intellectual Property - Personal Genome Diagnostics
 
Seth Andrew Wander
Consulting or Advisory Role - Foundation Medicine; InfiniteMD
 
Jorge Buendia-Buendia
No Relationships to Disclose
 
Karla Helvie
No Relationships to Disclose
 
Ursula A. Matulonis
Consulting or Advisory Role - 2X Oncology; Fujifilm; Geneos; Immunogen; Merck; Mersana; Myriad Genetics
Research Funding - Merck; Novartis; Syndax; Tesaro
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Macrogenics; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Celldex; Eisai; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology; Sanofi; Tesaro
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Carrick Therapeutics; Genentech/Roche; GlaxoSmithKline; InfiniteMD; Jounce Therapeutics; Jounce Therapeutics; Lilly; Tesaro
Consulting or Advisory Role - InfiniteMD; Leap Therapeutics
Research Funding - Genentech (Inst)
 
Alan D. D'Andrea
Stock and Other Ownership Interests - Ideaya, Inc.
Honoraria - Lilly; Sanofi
Consulting or Advisory Role - Biomarin; Deerfield Management; Ideaya, Inc.; Intellia Therapeutics; Third Rock Ventures; Vertex
Travel, Accommodations, Expenses - Biomarin; IDEAYA Biosciences; Lilly
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Astex Pharmaceuticals; Bayer; Bicycle Therapeutics; Cybrexa Therapeutics; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); CanBas (Inst); Cellceutix (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Nancy U. Lin
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - Genentech; Novartis; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases
 
Nikhil Wagle
Stock and Other Ownership Interests - Foundation Medicine
Honoraria - Lilly
Consulting or Advisory Role - Lilly; Novartis
Research Funding - Novartis; Puma Biotechnology